Drug Patent Settlement
Aurinia and Teva Settle Patent Dispute, Delaying Generic Voclosporin Launch Until 2036
Aurinia Pharmaceuticals has settled patent infringement litigation with Teva Pharmaceuticals over a generic version of voclosporin, the company's flagship drug for lupus kidney disease. Under the agreement, Teva may not launch its generic 7.9 mg voclosporin capsules in the US before December 7, 2036, when two key Aurinia patents expire National Post.
The settlement removes one competitor from Aurinia's path but leaves seven other generic makers still fighting patent claims. Rivals including Dr. Reddy's, Sandoz, and Hikma Pharmaceuticals continue their own legal challenges against Aurinia Financial Post.
What Voclosporin Is and Why It Matters
Voclosporin is an immunosuppressant drug developed by Aurinia to treat lupus kidney disease, a serious condition where the immune system attacks kidney tissues. The medication gained FDA approval in 2021 and became a key revenue driver for the smaller pharmaceutical company Toronto Sun.
Teva's Timeline: A 14-Year Delay from Now
Teva challenged Aurinia's patent protection by filing an Abbreviated New Drug Application, a legal path that allows generic makers to prove they can copy a drug without infringing patents Mitchell Advocate. Aurinia fought back in federal court, claiming Teva's generic would violate two key patents: U.S. Patent No. 10,286,036 and U.S. Patent No. 11,622,991 Recorder.
The settlement locks in Teva's launch date at December 7, 2036 — more than 14 years away — unless earlier events trigger the agreement's contingencies Edmonton Sun. This gives Aurinia years of market exclusivity for its most profitable drug.
Seven Other Generic Makers Still Battling Aurinia
Teva is no longer Aurinia's main competitor worry. The company faces separate patent infringement cases from Dr. Reddy's Laboratories, Sandoz, Hikma Pharmaceuticals USA, Zydus Pharmaceuticals, Lotus Pharmaceutical, Galenicum Health, and DifGen Pharmaceuticals Leader Post. Each company filed its own generic application and now faces Aurinia's legal challenge.
These cases follow the same pattern: generic makers argue they can copy voclosporin without breaking Aurinia's patents. Aurinia counters that any generic version will infringe the same two patents at the heart of the Teva deal Northern News. The outcomes will determine when cheaper voclosporin reaches patients Daily Herald Tribune.
What This Means for Aurinia's Revenue and Stock
The Teva settlement is a major win for Aurinia's bottom line. Voclosporin generated strong sales for the company since launch, and the patent agreement guarantees Aurinia will keep the market to itself until at least 2036 Financial Post. Patent settlements often boost stock prices because investors see longer profit protection.
However, the company must still win the remaining seven cases or reach separate settlements with each rival. If any generic maker wins its patent challenge before 2036, Aurinia's revenue could face a sharp hit. The litigation strategy now shifts to those contested cases Toronto Sun.
Sentiment
NeutralPublishers
15
Articles
15
Reach
15
